157 related articles for article (PubMed ID: 11000679)
41. [Applying distortion product otoacoustic emission in testing human sensory hearing loss].
Chen X; Zheng H; Zheng Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):382-4. PubMed ID: 15181843
[TBL] [Abstract][Full Text] [Related]
42. Noise in magnetic resonance imaging: no risk for sensorineural function but increased amplitude variability of otoacoustic emissions.
Wagner W; Staud I; Frank G; Dammann F; Plontke S; Plinkert PK
Laryngoscope; 2003 Jul; 113(7):1216-23. PubMed ID: 12838022
[TBL] [Abstract][Full Text] [Related]
43. Steady-state response audiometry in a group of patients with steeply sloping sensorineural hearing loss.
Ballay C; Tonini R; Waninger T; Yoon C; Manolidis S
Laryngoscope; 2005 Jul; 115(7):1243-6. PubMed ID: 15995514
[TBL] [Abstract][Full Text] [Related]
44. Comparison of auditory steady-state responses and auditory brainstem responses in audiometric assessment of adults with sensorineural hearing loss.
Lin YH; Ho HC; Wu HP
Auris Nasus Larynx; 2009 Apr; 36(2):140-5. PubMed ID: 18620826
[TBL] [Abstract][Full Text] [Related]
45. Effect of middle-ear effusion on otoacoustic emissions.
Yeo SW; Park SN; Park YS; Suh BD
J Laryngol Otol; 2002 Oct; 116(10):794-9. PubMed ID: 12437833
[TBL] [Abstract][Full Text] [Related]
46. Test-retest repeatability of distortion product otoacoustic emissions.
Wagner W; Heppelmann G; Vonthein R; Zenner HP
Ear Hear; 2008 Jun; 29(3):378-91. PubMed ID: 18382378
[TBL] [Abstract][Full Text] [Related]
47. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.
de Hoog M; van Zanten BA; Hop WC; Overbosch E; Weisglas-Kuperus N; van den Anker JN
J Pediatr; 2003 Jan; 142(1):41-6. PubMed ID: 12520253
[TBL] [Abstract][Full Text] [Related]
48. Audiological evaluation of affected members from a Dutch DFNA8/12 (TECTA) family.
Plantinga RF; Cremers CW; Huygen PL; Kunst HP; Bosman AJ
J Assoc Res Otolaryngol; 2007 Mar; 8(1):1-7. PubMed ID: 17136632
[TBL] [Abstract][Full Text] [Related]
49. [The acoustic distortion products application in noise pathology].
Morant Ventura A; Mata Peñuela JJ; Orts Alborch M; Postigo Madueño A; Marco Algarra J
An Otorrinolaringol Ibero Am; 2000; 27(4):341-52. PubMed ID: 11105335
[TBL] [Abstract][Full Text] [Related]
50. Progressive sensorineural hearing loss in children with mitochondrial encephalomyopathies.
Zwirner P; Wilichowski E
Laryngoscope; 2001 Mar; 111(3):515-21. PubMed ID: 11224785
[TBL] [Abstract][Full Text] [Related]
51. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.
Stavroulaki P; Vossinakis IC; Dinopoulou D; Doudounakis S; Adamopoulos G; Apostolopoulos N
Arch Otolaryngol Head Neck Surg; 2002 Feb; 128(2):150-5. PubMed ID: 11843723
[TBL] [Abstract][Full Text] [Related]
52. Objective evaluation of the effects of intravenous lidocaine on tinnitus.
Kalcioglu MT; Bayindir T; Erdem T; Ozturan O
Hear Res; 2005 Jan; 199(1-2):81-8. PubMed ID: 15574302
[TBL] [Abstract][Full Text] [Related]
53. Otoacoustic emissions in early noise-induced hearing loss.
Shupak A; Tal D; Sharoni Z; Oren M; Ravid A; Pratt H
Otol Neurotol; 2007 Sep; 28(6):745-52. PubMed ID: 17721363
[TBL] [Abstract][Full Text] [Related]
54. DPOAE-grams in patients with acute tonal tinnitus.
Gouveris H; Maurer J; Mann W
Otolaryngol Head Neck Surg; 2005 Apr; 132(4):550-3. PubMed ID: 15806043
[TBL] [Abstract][Full Text] [Related]
55. Distortion product otoacoustic emissions in an industrial setting.
Korres GS; Balatsouras DG; Tzagaroulakis A; Kandiloros D; Ferekidou E; Korres S
Noise Health; 2009; 11(43):103-10. PubMed ID: 19414930
[TBL] [Abstract][Full Text] [Related]
56. Otoacoustic emissions in patients with retrocochlear dysfunction: a report of five cases.
Ried EU; Ried EG; Avilés M
Ear Nose Throat J; 2000 Jun; 79(6):438, 441-4, 446. PubMed ID: 10893834
[TBL] [Abstract][Full Text] [Related]
57. Volterra Slice otoacoustic emissions recorded using maximum length sequences from patients with sensorineural hearing loss.
de Boer J; Thornton AR
Hear Res; 2006 Sep; 219(1-2):121-36. PubMed ID: 16887305
[TBL] [Abstract][Full Text] [Related]
58. Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions.
Md Daud MK; Mohamadl H; Haron A; Rahman NA
B-ENT; 2014; 10(1):53-8. PubMed ID: 24765829
[TBL] [Abstract][Full Text] [Related]
59. Ototoxicity caused by topical administration of gentamicin versus tobramycin in rabbits.
Oghan F; Apuhan T; Yılmaz F
Int J Pediatr Otorhinolaryngol; 2011 Jul; 75(7):915-8. PubMed ID: 21592592
[TBL] [Abstract][Full Text] [Related]
60. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
